UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Consensus Target Price from Brokerages

UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $43.70.

URGN has been the topic of a number of recent research reports. Oppenheimer reaffirmed an "outperform" rating and set a $40.00 price objective on shares of UroGen Pharma in a research report on Wednesday, October 16th. D. Boral Capital reiterated a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Friday, December 6th. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of UroGen Pharma in a research note on Tuesday, October 15th. Finally, EF Hutton Acquisition Co. I raised UroGen Pharma to a "strong-buy" rating in a research report on Monday, October 14th.

Institutional Investors Weigh In On UroGen Pharma

A number of institutional investors and hedge funds have recently modified their holdings of URGN. JPMorgan Chase & Co. increased its holdings in UroGen Pharma by 263.1% in the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock valued at $864,000 after buying an additional 49,318 shares in the last quarter. Tidal Investments LLC increased its stake in shares of UroGen Pharma by 19.1% in the 3rd quarter. Tidal Investments LLC now owns 37,595 shares of the company's stock valued at $477,000 after purchasing an additional 6,030 shares in the last quarter. Barclays PLC raised its holdings in UroGen Pharma by 409.3% in the 3rd quarter. Barclays PLC now owns 59,778 shares of the company's stock worth $759,000 after purchasing an additional 48,040 shares during the period. Geode Capital Management LLC raised its stake in shares of UroGen Pharma by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock worth $5,787,000 after buying an additional 34,248 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of UroGen Pharma during the 3rd quarter valued at approximately $297,000. Institutional investors and hedge funds own 91.29% of the company's stock.

UroGen Pharma Stock Up 1.2 %

Shares of NASDAQ:URGN traded up $0.13 during trading hours on Tuesday, hitting $10.65. The company's stock had a trading volume of 478,330 shares, compared to its average volume of 490,951. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm's fifty day moving average price is $11.84 and its 200 day moving average price is $13.71. UroGen Pharma has a 52 week low of $10.26 and a 52 week high of $20.70. The company has a market capitalization of $249.79 million, a price-to-earnings ratio of -3.38 and a beta of 1.06.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same period last year, the firm earned ($0.68) EPS. As a group, research analysts expect that UroGen Pharma will post -3.1 EPS for the current year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.